



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم

بسم الله الرحمن الرحيم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY

**Impact of Axillary Lymph Nodes Ratio on Outcomes of
Non Metastatic, Triple Negative Breast Cancer
Patients treated with Up Front Surgery (A
Retrospective Study)**

Thesis

*Submitted for Partial Fulfillment of Master Degree in
Clinical Oncology & Nuclear Medicine*

By

Asmaa Khalaf Ahmed Mohamed

M.B, B. Ch,

Under Supervision of

Prof. Dr.

Nivine Mahmoud Ahmed Gado

*Professor of Clinical Oncology & Nuclear Medicine,
Faculty of Medicine, Ain Shams University*

Dr.

Diaa el din Moussa sherif

*Lecturer of Clinical Oncology & Nuclear Medicine,
Faculty of Medicine, Ain Shams University*

Faculty of Medicine
Ain Shams University

2021

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

سُبْحَانَكَ لَا عِلْمَ لَنَا
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **Allah**, the Most Precious and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Niveen Mahmoud Ahmed Gado**, Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine-Ain Shams University, for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am deeply thankful to **Dr. Amr Lotfy Farag**, Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine-Ain Shams University, for his great help, active participation and guidance.*

*I am also delighted to express my deepest gratitude and thanks to **Dr. Dina El Din Moussa Sherif**, Lecturer of Clinical Oncology and Nuclear Medicine, Faculty of Medicine-Ain Shams University, for his kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I would like to express my hearty thanks to **my Husband and all my family** for their support till this work was completed.*

Last but not least my sincere thanks and appreciation to all patients participated in this study.

Asmaa Khalaf Ahmed

List of Contents

Title	Page No.
List of Tables.....	i
List of Figures	iii
List of Abbreviations.....	iv
Introduction	- 1 -
Aim of the Work	4
Review of Literature	
📖 Epidemiology of Breast Cancer.....	5
📖 Risk Factors	8
📖 Pathology of Breast Cancer.....	16
📖 Staging	25
📖 Prognostic Determinant	31
📖 Diagnosis.....	35
📖 Triple -ve Breast Cancer	42
📖 Treatment of Triple -ve Breast Cancer.....	49
📖 Axillary Lymph Nodes and Breast Cancer.....	57
📖 Axillary Lymph Node Ratio (ALNR)	61
Patients and Methods.....	64
Results.....	67
Discussion	95
Summary and Conclusion	101
Recommendations	102
References	103
Arabic Summary	--

List of Tables

Table No.	Title	Page No.
Table (1):	Anatomic Stage/Prognostic groups	30
Table (2):	Age	67
Table (3):	Age group	67
Table (4):	Menopause	68
Table (5):	Sidedness	68
Table (6):	Grade	69
Table (7):	Surgery	69
Table (8):	Tumor size	70
Table (9):	Nodal infiltration (N)	70
Table (10):	Removed lymph nodes(RLNS)	71
Table (11):	Negative lymph nodes (NLNs).....	71
Table (12):	Pathological Lymph nodes(PLNs)	71
Table (13):	Lymph node ratio (LNR)	72
Table (14):	Protocol	72
Table (15):	Taxane-based.....	73
Table (16):	Relapse.....	73
Table (17):	Local relapse only.....	74
Table (18):	Bone mets only	74
Table (19):	Visceral mets only	75
Table (20):	Bone and visceral mets	75
Table (21):	Local relapse and visceral mets.....	76
Table (22):	Death.....	76
Table (23):	Relation between LNR & age.....	77

List of Tables (Cont...)

Table No.	Title	Page No.
Table (24):	Relation between LNR & age group	78
Table (25):	Relation between LNR & menopause.....	78
Table (26):	Relation between LNR & sidedness	79
Table (27):	Relation between LNR & grade	80
Table (28):	Relation between LNR & surgery.....	81
Table (29):	Relation between LNR & Tumor size	82
Table (30):	Relation between LNR & protocols.....	83
Table (31):	Relation between LNR & taxane-based	84
Table (32):	Relation between LNR & relapse	85
Table (33):	Relation between LNR & local relapse with /without Visceral mets	86
Table (34):	Relation between LNR & bone mets only.....	87
Table (35):	Relation between LNR & Visceral mets only.....	88
Table (36):	Relation between LNR & bone and visceral mets.....	89
Table (37):	Relation between LNR & death.....	90
Table (38):	Mean and median disease free survival of all patients	91
Table (39):	Relation between DFS & LNR.....	92
Table (40):	Mean and median OS of all patients	93
Table (41):	Relation between OS & LNR	94

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Mammogram and MRI Breast Images Comparison.....	38
Figure (2):	Disease free survival of all patients.	91
Figure (3):	Disease free survival & LNR.	92
Figure (4):	Over all survival of all patients.	93
Figure (5):	Over all survival & LNR.	94

List of Abbreviations

Abb.	Full term
<i>ALNR</i>	<i>Axillary Lymph Nodes Ratio</i>
<i>BRCA1</i>	<i>Breast Cancer Gene One</i>
<i>CNB</i>	<i>Core Needle Biopsy</i>
<i>DCIS</i>	<i>Ductal Carcinoma in Situ</i>
<i>EPT</i>	<i>Estrogen-Progestin Therapy</i>
<i>ER</i>	<i>Estrogen Receptor</i>
<i>ET</i>	<i>Estrogen Therapy</i>
<i>FNAB</i>	<i>Fine Needle Aspiration Biopsy</i>
<i>HER2</i>	<i>Human Epidermal Growth Factor 2</i>
<i>HT</i>	<i>Hormone Therapy</i>
<i>IDC</i>	<i>Infiltrating Ductal Carcinoma</i>
<i>ILC</i>	<i>Infiltrating Lobular Carcinomas</i>
<i>LCIS</i>	<i>Lobular Carcinoma in Situ</i>
<i>LN</i>	<i>Lymph Node</i>
<i>LNR</i>	<i>Lymph Node Ratio</i>
<i>LVI</i>	<i>Lymphatic and Vascular Invasion</i>
<i>M0</i>	<i>Metastatic Disease</i>
<i>MRI</i>	<i>Magnetic Resonance Imaging</i>
<i>NCI</i>	<i>National Cancer Institute</i>
<i>pKi67</i>	<i>Ki67 Protein</i>
<i>PR</i>	<i>Progesterone Receptor</i>
<i>SEER</i>	<i>Surveillance, Epidemiology, and End Results</i>
<i>SLN</i>	<i>Sentinel Lymph Node</i>
<i>TNBC</i>	<i>Triple-Negative Breast Cancer</i>

INTRODUCTION

Breast cancer is the most common malignant tumor among females around the world and the second common type of malignancies. It represents 1.7 million new cases per year and 25% of all types of cancers (*Balekouzou et al., 2016*).

According to, (pathological based statistics); 252,710 new cases were diagnosed with breast cancer among women in USA by the end of 2017, also approximately 40, 610 women died from breast cancer in 2017 (*DeSantis et al., 2017*).

In Egypt, breast cancer is the most common cancer among females . According to, The Egypt National Cancer Institute (NCI) ; among 10, 556 patients at the end of 2001, breast cancer representing 18.9% of total cancer cases (35.1% in females and 2.2% in males) (*Amal et al., 2014*).

The molecular classification of breast cancer (luminal, basal-like, HER2-positive enriched and normal-like) was the most important researching issue in the field of breast cancer (*Cheang et al., 2015*).

The Triple-Negative Breast Cancer (TNBC) subtype representing about 15% of all breast cancers. It characterized by loss of expression of both Estrogen and Progesterone

Receptors and lack of over expression or amplification of the HER2/neu oncogene (*Perou, 2011*).

TNBC often shows a more aggressive course than other molecular subtypes and poorer disease-specific survival with higher rates of recurrence(visceral and central nervous system metastases) (*Bianchini et al., 2016*).

Axillary lymph node (LN) status is considered one of the most significant prognostic factors in breast cancer, it is mainly depended on the absolute number of involved LNs (*Li et al., 2012*).

Inadequate lymph nodes dissection may lead to under staging of the axilla so, It has been well established that the number of dissected axillary LNS is an important factor in prognosis of breast cancer (*Ahn et al., 2011*).

It is generally accepted that adequately assessment of axilla need to more than 10 LNS (*National Comprehensive Cancer Network (NCCN), 2015*).

Lymph node ratio (LNR) is defined as the number of positive lymph nodes divided by the number of lymph nodes examined (*Vinh-Hung et al., 2004*).

Many studies reported a large variation in the cutoff points used to differentiate breast cancer patients in risk groups

according to their LNR, Some studies divided the patients into 2 LNR risk groups, whereas others divided them into 3 LNR risk groups (*Kim et al., 2013*).

In a big study analyzed data of 1, 829 node positive breast cancer patients, they divided patients into 3 LNR risk groups; low-risk [<0.20], intermediate-risk [$0.21-0.65$], and high-risk [>0.65] LNR groups (*Vinh-Hung et al., 2009*).

Studies have demonstrated that LNR, which takes into consideration the adequacy of LN dissection, may enhance risk stratification, Some studies reported that the LNR system predicted prognosis better than pN system (using pN1–3 classification), so they suggested that LNR should be considered as an alternative to pN staging (*Vinh-Hung et al., 2009; Danko et al., 2010*).

In another study, LNR is considered has a better prognostic value than the absolute number of involved axillary LNs (*Xiao et al., 2013*).

The prognostic value of the LNR has already been well established for other malignancies, including colorectal cancer and pancreatic cancer (*Jiang et al., 2019; Elshaer et al., 2019*).

AIM OF THE WORK

This is a retrospective study, The primary aim of this study is to assess the disease free survival and overall survival among the study group (non metastatic, triple negative breast cancer patients treated with upfront surgery) in relation to different axillary lymph node ratios.

The secondary objective is to assess the impact of axillary lymph nodes ratio on the pattern of relapse (loco-regional and metastatic).